Cannabinoid receptor type 1 (CB1) antibodies, encoding nucleic acid molecules thereof and methods of use thereof
The present disclosure provides isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragment thereof. The CB1 binding proteins find utility in the treatment and diagnosis of CB1 mediated conditions, diseases and disorders.
1. An isolated antibody or antigen-binding fragment thereof that binds human cannabinoid type 1 receptor (CB1) (SEQ ID NO:1), the antibody or antigen-binding fragment thereof comprising six complementarity determining regions (CDRs): CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein
CDR-H1 has an amino acid sequence G-Y-T-F-T-D-Y-W (residues 26-33 of SEQ ID NO:329) or a modification of said amino acid sequence by a substitution of at least one amino acid residue, wherein the substitution of G at position 1 is S; the substitution of T at position 3 is E; the substitution of T at position 5 is S or N; the substitution of D at position 6 is R or Y; the substitution of Y at position 7 is H; and the substitution of W at position 8 is A or N;
CDR-H2 has an amino acid sequence I-Y-P-Y-D-G-D-T (residues 51-58 of SEQ ID NO:329) or a modification of said amino acid sequence by a substitution of at least one amino acid residue, wherein the substitution of I at position 1 is F; the substitution of Y at position 2 is D, S, or T; the substitution of P at position 3 is T; the substitution of Y at position 4 is G, D, or S; the substitution of D at position 5 is Y or S; the substitution of G at position 6 is S; the substitution of D at position 7 is E, G, or R; and the substitution of T at position 8 is A, S, or I;
CDR-H3 has an amino acid sequence A-R-G-X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -X 8 -X 9 -W-X 10 -X 11 -Y (residues 98-113 of SEQ ID NO:329) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein the substitution of A at position 1 is S; the substitution of G at position 3 is S; X 1 at position 4 is Q, Y, K, R, or G, or is not present; X 2 at position 5 is E, Y, L or G, or is not present; X 3 at position 6 is Y or P, or is not present; X 4 at position 7 is Y, R, or E, or is not present; X 5 at position 8 is G, or is not present; X 6 at position 9 is T, or is not present; X 7 at position 10 is N or D, or is not present; X 8 at position 11 is Y, N, A, or G, or is not present; X 9 at position 12 is N, Y, S, A, or R, or is not present; the substitution of W at position 13 is Y, A, or P; X 10 at position 14 is L, M, F, or G, or is not present; X 11 at position 15 is P, D, A, or T, or is not present; the substitution of Y at position 16 is V;
CDR-L1 has an amino acid sequence Q-X 1 -I-S-S-X 2 -Y (residues 27-33 of SEQ ID NO:330) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein the substitution of Q at position 1 is S or E; X 1 at position 2 is E, S, T, N, G, or R; the substitution of I at position 3 is V; the substitution of S at position 4 is A, R, or G; the substitution of S at position 5 is G, N, or T; X 2 at position 6 is S, N, the peptide F-R-Y-S, or is not present; and the substitution of Y at position 7 is F, D, or N;
CDR-L2 has an amino acid sequence: X 1 -T-S (residues 51-53 of SEQ ID NO:330) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein X 1 at position 1 is A, Y, G, R, D, or S; the substitution of T at position 2 is A; the substitution of S at position 3 is R; and
CDR-L3 has an amino acid sequence: Q-Q-Y-X 1 -S-X 2 -P-Y-T (residues 91-99 of SEQ ID NO:330) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein the substitution of Q at position 1 is L or H; the substitution of Q at position 2 is H; the substitution of Y at position 3 is S or G; X 1 at position 4 is S, W, H, Y, N, or I; the substitution of S at position 5 is E, R, G, T, or N; X 2 at position 6 is Y, I, S, T, L, or W; and the substitution of Y at position 8 is P, L, F, or is not present;
wherein said substitution of at least one amino acid residue does not inhibit the ability of said antibody or antigen-binding fragment thereof to bind human CB1.
2. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises the (HCDR set/LCDR set) pair selected from the group consisting of SEQ ID NOs: (20, 21, 22/26, 27, 28); (32, 33, 34/38, 39, 40); (44, 45, 46/50, 51, 52); (56, 57, 58/62, 63, 64); (68, 69, 70/74, 75, 76); (80, 81, 82/86, 87, 88); (92, 93, 94/98, 99, 100); (104, 105, 106/110, 111, 112); (116, 117, 118/122, 123, 124); (128, 129, 130/134, 135, 136); (140, 141, 142/146, 147, 148); (152, 153, 154/158, 159, 160); (164, 165, 166/170, 171, 172); (176, 177, 178/182, 183, 184); (188, 189, 190/194, 195, 196); (200, 201, 202/206, 207, 208); (212, 213, 214/218, 219, 220); (224, 225, 226/230, 231, 232); (236, 237, 238/242, 243, 244); (248, 249, 250/254, 255, 256); (260, 261, 262/266, 267, 268); (272, 273, 274/278, 279, 280); (284, 285, 286/290, 291, 292); (296, 297, 298/302, 303, 304); (308, 309, 310/314, 315, 316); and (320, 321, 322/326, 327, 328).
3. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises the HC/LC pair selected from the group consisting of SEQ ID NOs: 17/23, 29/35, 41/47, 53/59, 65/71, 77/83, 89/95, 101/107, 113/119, 125/131, 137/143, 149/155, 161/167, 173/179, 185/191, 197/203, 209/215, 221/227, 233/239, 245/251, 257/263, 269/275, 281/287, 293/299, 305/311, and 317/323.
4. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence, wherein the VH domain sequence has at least 95% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 18, 30, 42, 54, 66, 78, 90, 102, 114, 126, 138, 150, 162, 174, 186, 198, 210, 222, 234, 246, 258, 270, 282, 294, 306, and 318; and the VL domain sequence has at least 95% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, and 324.
5. The isolated antibody or antigen-binding fragment thereof of claim 4 , wherein the VH domain sequence is set forth in an amino acid sequence selected from the group consisting of SEQ ID NOs: 114, 126, 138, 150, 162, 90, 186, 198, 210, 222, 234, 246, 258, 270, 282, 294, 306, and 318, and the VL domain sequence is set forth in an amino acid sequence selected from the group consisting of SEQ ID NOs: 120, 132, 144, 156, 168, 96, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, and 324.
6. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the fragment comprises a Fab fragment, a Fab′ fragment, a F(ab) 2 fragment or a scFv fragment.
7. The isolated antibody or antigen-binding fragment thereof claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a human Fc region selected from the group consisting of an IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM Fc.
8. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a modified human Fc region.
9. The isolated antibody or antigen-binding fragment thereof of claim 8 , wherein the modified human Fc region comprises a mutation selected from the group consisting of L234A/L235A, S228P, A330S, P331S, E233P/L234V/L235A, A327G/A330S/P331S, L234F/L235E/P331S, and N297Q.
10. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is a humanized antibody.
11. A multispecific binding protein comprising an antigen-binding fragment of claim 1 .
12. An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof of claim 1 .
13. An expression vector comprising the nucleic acid molecule of claim 12 .
14. A isolated host cell comprising the expression vector of claim 13 .
15. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof of claim 1 and at least one pharmaceutically acceptable excipient.
16. A method of modulating CB1 signaling, the method comprising contacting a cell expressing CB1 with the antibody or antigen-binding fragment thereof of claim 1 .
17. A method for inhibiting the biological activity of CB1 in a subject in need thereof, comprising administering to the subject in need there of an effective amount of a pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof of claim 1 thereby inhibiting the activity of the CB1 protein in the subject.
18. A method for treating a disease or disorder associated with CB1 activity, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the disease or disorder is selected from the group consisting of obesity, syndromic obesities, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease, primary biliary cirrhosis, kidney fibrosis, chronic kidney disease, focal segmental glomerulosclerosis, and diabetic nephropathy.